309 results about "Blood plasma fractionation" patented technology

The invention provides a system for preparing an autologous solid-fibrin web suitable for regenerating tissue in a living organism. The system includes a sealed primary container containing a separation medium and a low-density high-viscosity liquid. The separation medium separates red blood cells from plasma when the container contains blood and is centrifuged, and the primary container has a first pressure. The system further includes a sealed secondary container containing a calcium-coagulation activator. The secondary container has a second pressure that is less than the first pressure. The system also comprises a transfer device including a cannula having a first end and a second end. The first and second ends puncture the sealed primary and secondary containers in order to provide fluid communication between the first and second containers. The low-density high-viscosity liquid of the primary container blocks flow through the cannula upon entering therein.

A method for carrying out therapeutic apheresis comprises separating plasma from whole blood in-vivo and removing selected disease-related components from the separated plasma. Apparatus for carrying out therapeutic apheresis includes a filter device for being implanted in a blood vessel for carrying out in-vivo plasma separation having one or more elongated hollow tubes and a plurality of elongated hollow microporous fibers capable of separating plasma from whole blood at pressure and blood flow within a patient's vein, a multiple lumen catheter secured to the proximal end of the filter device having one or more lumens in fluid communication with the interior of said one or more hollow tubes and a plasma return lumen, and therapeutic apheresis apparatus for removing and/or separating selected disease-related components from the separated plasma and means for directing plasma between said catheter and the selective component removal apparatus.

Provided is a disposable multi-layered filtration device for the separation of blood plasma which can be applied to a biochip and appropriate for disposal uses. The filtration device for the separation of blood plasma includes: an upper substrate including a blood inlet; an intermediate substrate including a filtering unit for extracting blood plasma from blood flowing through the blood inlet; and a lower substrate including an air outlet, wherein the upper substrate, the intermediate substrate, and the lower substrate are stacked and adhered.

The invention provides methods and devices for the capture and removal of target biomolecules from a patient's body fluid, particularly blood or a blood component, using a partial imprint material. The partial imprint material is composed of a matrix composition having partial imprint cavities that correspond to a segment of a target biomolecule but which are capable of removing the entire target biomolecule from the body fluid. The method can be implemented by removing a volume of a patient's body fluid, e.g., blood, bringing the body fluid or a component thereof into contact with the partial imprint material under conditions effective to capture the target biomolecule, and returning the body fluid to the patient. A modified dialysis or apheresis device can be used in which the body fluid is removed, continuously passed through a circuit containing the partial imprint material, and re-introduced into the patient's body following treatment.

The invention relates to a method for separating and purifying human immunoglobulin from a component I+III of blood plasma, and aims to provide a high-efficiency method for recovering high-purity human immunoglobulin. According to the technical scheme provided by the invention, the method comprises the following steps of: a, fully dissolving component I+III precipitate; b, precipitating with octylic acid and removing lipid and a part of impurity protein to prepare IgG (Immunoglobulin G); c, purifying through anion exchange column chromatography; and d, collecting flow-through liquid, performing membrane nanofiltration, ultrafiltration and concentration, preparing the human immunoglobulin, sterilizing and packaging. The method has the beneficial effects of capability of being operated at the room temperature, simple and short steps, high yield, low energy consumption and high output and is suitable for mass production; comprehensive utilization of the blood plasma is fully realized; the time of the entire production process is shortened; the cost is reduced; extremely considerable economic benefit can be produced; the safety of a product is guaranteed by using two virus inactivation/elimination methods of different mechanisms; the environmental pollution is avoided; and the method has high economic and social values.

Blood is purified by removing the whole blood from a patient and feeding the blood into a manifold in a centrifuge. A purifying chamber is formed in the centrifuge from a plurality of co-arcuately arranged modules. The blood is supplied from the manifold to each of the modules. Each module contains a stack of dialysate membranes. Fresh dialysate is fed into the manifold and then to each of the modules. Under centrifugal force the cells are separated from the plasma. The plasma is purified by removing contaminants as a result of the action of the dialysate and membranes. The purified blood is returned to the patient by being fed back to the manifold and then to the patient. The used dialysate/contaminants are fed from the modules back to the manifold and out of the centrifuge.

The invention provides a method to reduce the rate of tumor metastasis and tumor recurrence after surgery and chemotherapy and radiotherapy by removing circulating tumor cells (CTC) in the blood after surgery and chemotherapy and radiotherapy by means of specificity, thereby improving the survival rate of cancer patients. The invention provides a method and a system for removing tumor cells. Patients ' blood is guided out to pass through a container, an antibody or a ligand capable of combining with the specificity of the tumor cells is fixed on a solid-phase carrier in the container, whne the patients ' blood passes through the container, the tumor cells can be absorbed by the specificity to be unable to flow back to patients ' blood, and then the tumor cells are removed from the blood to reduce the recidivation of tumor patients and to prolong their survival rate. The removed tumor cells can be washed out from the solid-phase carrier for counting. The invention further provides a method to remove pathogen from blood. Blood is withdrawn from a patient and its plasma and cellular components are separated by means of a plasma separator under the effect of a blood pump, the plasma portion inactivates the pathogen in the blood via a pathogen inactivating device, flows back to extracorporeal circulation passage to merge with the cellular components and then is returned to the patient. The method adopts a physical means, so that side effects can be reduced. The device is simple in structure and can be connected with other blood purification devices.

The invention discloses a plasma exchanging adsorption filtration purification system provided with a plasma storage bag and an application method of the purification system. The method includes two steps of plasma components separation returning cycle and high-speed plasma purification regeneration cycle. Plasma components are separated by a selective membrane plasma separator; flow speed difference between a plasma separation cycle and a plasma purification circle is set by the specific plasma storage bag; high-speed plasma adsorption filtration purification treatment is performed by a high-throughput filter and an active carbon-resin absorptive device in a purification circle; and plasma subjected to cycle treatment for multiple times can be exchanged back to a human body through the separation returning circle. By the aid of the purification system and the application method thereof, autologous plasma waste generated in a plasma exchanging purification process can be purified continuously and effectively, and plasma consumption is reduced. The high-throughput filter and an adsorption column are connected in series to purify the plasma; load on a subsequent adsorber is reduced; and varied inflammatory factors, macromolecular toxins and the like combined by micromolecules, middle molecules and proteins which are generated from hepatic failure are eliminated as well, so that the purification efficiency of the whole system is greatly improved.

The invention discloses a whole blood centrifugal separation chip and a preparation method thereof and belongs to the field of micro-electromechanical system. A vortex-type microfluid passage is arranged on the chip; a sample inlet is arranged in the passing center of the microfluid passage; at least one row of micro upright post rails are arranged in the microfluid passage; the microfluid passage is divided into two or more flow passages by the micro upright post rails; and the flow passages are connected with different sample outlets. By pouring the whole-blood sample into the centrifugal separation chip through a micro pump, cells and blood plasma are separated by gaps between the micro upright post rails; the structure of the chip is compact, so the total area of the chip is reduced; the separating efficiency is enhanced; and the separating process of the chip costs a short time.

A composition for blood serum or plasma separation which has improved compatibility between a cyclopentadiene oligomer and a phthalic ester and generates no oily ingredient suspending in the blood serum or plasma after centrifugal separation regardless of the conditions for the centrifugal separation; and a vessel for blood examination which contains the composition. The composition for blood serum or plasma separation comprises: a polycyclic hydrocarbon compound having an unsaturated and/or saturated cyclic structure in the molecule and having a solidifying point or pour point of 0° C. or lower; a cyclopentadiene oligomer; and a phthalic ester.

The invention relates to the field of medical devices, and particularly provides a device for eliminating pathogens in blood. The device for eliminating the pathogens in the blood comprises an external circulation path consisting of a blood exhalant (1), a plasma separator (2) and a blood return pipe (3) which are sequentially connected, and further comprises a pathogen physical deactivation device (5) connected with the external circulation path. The invention further provides a method for eliminating the pathogens in the blood, comprising the following steps: after the blood flows out from a patient body, blood cells and plasma in the blood are separated by the plasma separator; and after the pathogens in the plasma are physically deactivated through the pathogen physical deactivation device, the plasma flows back to the external circulation path and then flows back to the patient body in combination with the blood cells. The method adopts physical means and can reduce side effects. The device is simple in structure, and can be connected with other blood purification devices for use.

A corpuscle/plasma separating part is disposed at the lower end of the substrate, and a sensor part connected to the corpuscle/plasma separating part is disposed at the upper end of the substrate, with a calibration solution reservoir being disposed on the lower side of the sensor part, and a calibration solution waste reservoir being disposed on the upper side of the sensor part. A first centrifugal axis is located upper to the corpuscle fraction storing part and lower to the plasma fraction storing part of the corpuscle/plasma separating part, while a second centrifugal axis is located within or close to the sensor part. Conveyance and discharge of the calibration solution can be carried out by performing centrifugation around the first centrifugal axis which is distant from the sensor part at a low speed of rotation, so that the centrifugal force exerted on the sensors would be small. During the centrifuge operation at a high speed of rotation for the separation of blood corpuscles, centrifugation can be performed around the second centrifugal axis so that the centrifugal force exerted on the sensors is small. Centrifuge operation allows separation of the blood corpuscles and blood plasma, and conveyance of the blood plasma and the calibration solution, as Well as certain discharge of the calibration solution from the sensors, thereby allowing precise analysis. Any damage in the sensors due to strong centrifugal force during the separation of blood corpuscles and blood plasma can be prevented.

A method for separating components from plasma, the method comprising (I) separating the plasma into a first and second component, the first component comprising an albumin/alpha-1-antitrypsin pool and the second component comprising plasma containing components having a molecular mass greater than albumin; (II) treating the second component to form an immunoglobulins concentrate containing immunoglobulins substantially free from components having a molecular mass less than immunoglobulins; (III) treating the immunoglobulins concentrate to remove components having a molecular mass greater than immunoglobulins; and (IV) separating albumin and alpha-1-antitrypsin from the albumin/alpha-1-antitrypsin pool.

The invention discloses a plasma separating chip, and belongs to the field of micro electro mechanical systems. The chip is provided with a micro spiral fluid channel, and a centre around which the micro fluid channel bypasses is provided with a sample inlet; the inner side at a certain position of the micro fluid channel is connected with another concentric micro spiral fluid channel; a plurality of gradient channels are arranged between the two micro spiral fluid channels; and the two micro spiral fluid channels are connected with two different sample outlets. A mixture of different sizes of cells or particles is injected through the sample inlet of the plasma separating chip by a micro pump or an injection pump; and the cells and plasma in the blood are separated into two different circulation channels by inertial characteristics of the fluid and a pressure difference between the inner and outer channels. The plasma separating chip has a compact structure; the total area of the chip is reduced, and the separating efficiency is improved; and time is short in the separating process of the chip.

This invention aims at providing a plasma lipid composition selective adsorption separation porous membrane carrier materials, preparation methods and related applications. The porous membrane carrier used the average pore size of 0.05 m ~ 100 u medical nonwoven polymer as the starting raw materials, through a total of 60 Co-ray irradiation grafting copolymerization polyacrylic acid surface modification, it further fixed the cholesterol ligand by carboxyl of 1 - (3 - dimethyl amino-propyl ) -3 - ethyl activated carbon Diimide and biocompatibility ligand adsorption of heparin covalent coupling, finally get the polymer porous membrane carrier materials of plasma lipid selective adsorption separation ability. The invention related to the preparation method is simple, safe, effective and easy to promote large-scale production. With good material blood compatibility, it can be used as a plasma lipid composition adsorption separation of hyperlipidemia, dynamic perfusion of clinic high plasma patients' blood purification and waste blood separation renewable auxiliary materials.

The invention belongs to the technical field of biomedicine, and provides a bioartificial liver system. The system comprises a plasma separation / retransformation circulation part and a biological liver circulation part. The two parts are connected with each other through a circulation pipeline. The biological liver circulation part comprises a constant-temperature box with a heat preservation effect, a double-cavity blood storage bag, an oxygenation column, a plasma circulating pump, a dissolved oxygen monitoring and temperature instrument and a flow guide type micro capsule suspended fluidized bed bioreactor, wherein the double-cavity blood storage bag, the oxygenation column, the plasma circulating pump, the dissolved oxygen monitoring and temperature instrument and the flow guide type micro capsule suspended fluidized bed bioreactor are sequentially connected to form a circulating system. By means of a turbine flow guide type inlet, flow distribution is carried out on a part of high-speed fluid of the inlet by the bioreactor, lateral shear force borne by micro capsules in a fluid force field is effectively reduced, damage to the micro capsules is reduced, and contact efficiency of cells cultured in the bioreactor and perfusate is improved. The bioreactor is used for bioartificial liver supportive treatment system in order to obtain more ideal effects on the aspects of treating serious hepatitis, hepatic insufficiency and other diseases.

The invention refers to microfluidic separation of plasma for colormetric assay. A device includes a plasma separation membrane (110), a capillary channel (115) positioned adjacent the plasma separation membrane to receive plasma from blood placed on the plasma separation membrane, at least one cuvette (125, 245, 250, 255, 260, 332, 334, 336, 338, 342, 344, 346, 348, 420, 425, 430, 435.540, 545, 550, 555, 650, 652, 656) coupled to the capillary channel, a gas permeable membrane (150, 270, 350, 355, 622), and a distribution channel (120, 230, 235, 240, 325, 330, 525, 530, 545, 630) coupled to the capillary channel to provide plasma to the cuvette, wherein the cuvette is configured to hold an amount of plasma with reagent suitable for colorimetric assay by a tester to hold the device. Variations include the use of a quantiation channel (612) to provide a selected amount of plasma and a mixing channel (616) to mix plasma with a diluent.

It is intended to provide a microchannel for separating blood plasma whereby blood plasma can be conveniently separated on a microchip. A microchannel comprising: a substrate body (10a); a separation channel (11) which is formed within the substrate body (10a) and extended in the direction parallel to the longitudinal direction of the substrate body (10a); at least two (first and second) connection ports (13a, 14a) which are formed at one end of the separation channel (11) close to the thickness direction perpendicular to the longitudinal direction of the substrate body (10a); and first and second branch channels (13, 14) which are formed within the substrate body (10a) and connected respectively to the first and second connection ports (13a, 14a). In the state where the substrate body (10a) is extended perpendicular to the direction of gravitational force, a blood sample containing blood cells and plasma is flown from one end (11a) side of the separation channel (11). Before the blood sample attains the other end (11b) of the separation channel (11), the blood cells in the blood sample settle out. The blood cells having settled out are then introduced into the branch channel (14)that is located lower in the direction of gravitational force between the first and second branch channels. On the other hand, the major portion of the blood plasma is introduced into the other branch channel (13) located upper in the direction of gravitational force.

A simple and robust on-chip blood plasma separation device is provided. The device is configured to integrate with downstream detection modules and provides sample-to-answer microfluidic POC diagnostics devices.

The invention relates to hydrophilic membranes which are supplemented or treated with a non-ionic surfactant and processes for preparing such membranes. The membranes are particularly suitable for plasma separation or for haemodialysis and haemodiafiltration, but can also advantageously be used in other applications. Accordingly, the invention is further directed to the use of such membranes for plasma separation, plasma filtration, micro filtration, plasma therapy, haemodialysis and haemodiafiltration or cell filtration applications, respectively. The treated hydrophilic membranes show excellent biocompatibility, such as reduced platelet drop and decreased TAT levels.